James A. Lebovitz

In the last few years alone, Mr. Lebovitz has advised on a wide range of transactions, including:

• FS/KKR Advisor in its merger of FS KKR Capital Corp. (NYSE:FSK) and FS KKR Capital Corp. II (NYSE:FSKR), two publicly-listed business development companies (BDCs), creating one of the largest BDCs in the U.S. with $14.9 billion in assets under management.
  
• FS Investment Corporation (NYSE: FSIC) in its merger with Corporate Capital Trust, Inc. (NYSE: CCT), two publicly-listed BDCs advised by FS/KKR Advisor, to create the second largest publicly-traded BDC by assets under management. 
• HFF, Inc. (NYSE: HF) in its US$2 billion acquisition in a cash and stock merger with Jones Lang LaSalle (NYSE: JLL).
• FS Investment Corporation II, FS Investment Corporation III, FS Investment Corporation IV and Corporate Capital Trust II in their merger to create the second largest BDC by assets under management.
• JetPay Corporation (NASDAQ: JTPY), a leading provider of vertically integrated solutions for businesses including card acceptance, processing, payroll, payroll tax filing, human capital management services, and other financial transactions, in connection with its US$184 million acquisition by NCR Corporation (NYSE: NCR). Previously advised JetPay on several financings and transactions, which were preceded by the representation of Universal Business Payment Solutions Acquisition Corporation, a special purpose acquisition company (SPAC), in its US$72 million initial public offering of common stock, and subsequent acquisition of two operating companies, Jet Pay, a real-time card and ACH processor as well as merchant account provider, and A D Computer, a comprehensive payroll and tax filing service.
• Bravo Brio Restaurant Group, Inc. (Nasdaq: BBRG), the owner and operator of two Italian restaurant brands (BRAVO! Cucina Italiana and Brio Tuscan Grille), in its US$161 million initial public offering and US$74 million secondary offering, followed by its ultimate US$100 million going-private sale to Spice Private Equity.
• FS Investments, a leading alternative investment manager, in connection with its partnership with KKR, a leading global investment firm, to create the largest business development company (BDC) platform, with US$18 billion in combined assets under management. 
• FS Investment Corporation, FS Energy & Power Fund, FS Investment Corporation II, FS Investment Corporation III, and FS Investment Corporation IV, five business development companies, in connection with their continuous offerings of US$2.6 billion, US$1.5 billion, US$2 billion, US$4 billion and US$2.6 billion, respectively, of their common stock.
• Covance Inc., a leading clinical research organization (CRO) providing drug development services, in its: US$2.2 billion ten-year strategic alliance with Sanofi-Aventis and its related US$25 million acquisition of Sanofi's research and development sites in Porcheville, France and Alnwick in the United Kingdom, US$1.6 billion ten-year strategic alliance with Eli Lilly and Company, and its acquisition of the Gene Expression Laboratory from Merck.
• Adolor Corporation, a biotechnology company, in its US$415 million sale to Cubist Pharmaceuticals Inc., which included an innovative contingent payment right valued at up to US$225 million. Previously advised Adolor on its initial public offering and subsequent follow-on offerings of common stock as well as M&A transactions and general corporate matters.
• HFF, Inc., a commercial real estate capital intermediary, in its US$257 million initial public offering of Class A common stock and secondary offerings of common stock.
• Underwriters, led by JP Morgan and Goldman Sachs, in connection with numerous public offerings of common stock by Amicus Therapeutics, Inc. (NASDAQ: FOLD), a biopharmaceutical company focused on rare genetic diseases.

• 2021 Permanent & Private Capital Summit — Virtual Conference (June 2-3, 2021)
• Permanent and Private Capital in the Time of COVID-19: Where We've Been and Where We're Going — Dechert LLP, Virtual Conference (August 20, 2020)
• 2017 Permanent Capital Summit — Dechert LLP, New York , NY (March 08, 2017) 
• Current Trends in Permanent Capital: What Alternative Managers Need to Know Now — Dechert LLP, New York, NY ( January 22, 2015) 
• Forging a Launch Pad for Emerging Growth IPOs — The Burrill Report Podcast, Philadelphia, PA (April 06, 2012)
• Investments in Russian Pharma Market — Russian-American Pharmaceutical Conference, Philadelphia, PA (April 27, 2010)